RVV — Revive Therapeutics Income Statement
0.000.00%
Last trade - 00:00- CA$6.54m
- CA$6.58m
Annual income statement for Revive Therapeutics, fiscal year end - June 30th, CAD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 20.3 | 17.9 | 6.39 | 5.61 | 11 |
| Operating Profit | -20.3 | -17.9 | -6.39 | -5.61 | -11 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -20.1 | -17.8 | -6.32 | -5.62 | -11 |
| Net Income After Taxes | -20.1 | -17.8 | -6.32 | -5.62 | -11 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -20.1 | -17.8 | -6.32 | -5.62 | -11 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -20.1 | -17.8 | -6.32 | -5.62 | -11 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.069 | -0.056 | -0.016 | -0.009 | -0.004 |